标题
c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
作者
关键词
-
出版物
Cancers
Volume 12, Issue 6, Pages 1489
出版商
MDPI AG
发表日期
2020-06-09
DOI
10.3390/cancers12061489
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
- (2019) Alberto Ocana et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
- (2019) Ben C. Creelan et al. BRITISH JOURNAL OF CANCER
- Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation
- (2019) Masami Nozaki et al. Cancers
- Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations
- (2019) Riyaz Shah et al. Clinical Lung Cancer
- c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo
- (2018) Longquan Lou et al. CANCER SCIENCE
- The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer
- (2018) Takao Nakanishi et al. Cancer Medicine
- Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results
- (2017) Dana B. Cardin et al. INVESTIGATIONAL NEW DRUGS
- Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition
- (2017) Mei Hua Jin et al. MOLECULAR CANCER THERAPEUTICS
- Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis
- (2017) L Jin et al. ONCOGENE
- IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer
- (2017) L.P. Stabile et al. ORAL ONCOLOGY
- The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
- (2017) Yuichi Murakami et al. Oncotarget
- Positive feedback regulation between IL10 and EGFR promotes lung cancer formation
- (2016) Tsung-I Hsu et al. Oncotarget
- Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
- (2016) Marco Perez et al. Oncotarget
- Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer
- (2015) Hye-Young Min et al. Molecular Cancer
- Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
- (2015) JUAN XIAO et al. Molecular Medicine Reports
- Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways
- (2015) Yi-Hua Lai et al. Oncotarget
- Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
- (2015) Luigi Formisano et al. Oncotarget
- Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) Sheng-Yi Lin et al. PLoS One
- A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
- (2014) Zhenfeng Duan et al. BMC CANCER
- Erlotinib, Erlotinib-Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
- (2014) N. D. Gross et al. CLINICAL CANCER RESEARCH
- Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer
- (2014) T. Yoshida et al. CLINICAL CANCER RESEARCH
- Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models
- (2013) Sarah Elizabeth Wheeler et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845
- (2013) Ken-ichi Sato INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
- (2012) L. P. Stabile et al. CLINICAL CANCER RESEARCH
- Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines
- (2012) Ping Fan et al. EUROPEAN JOURNAL OF CANCER
- Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells
- (2011) Yun-Jung Park et al. BMB Reports
- Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells
- (2011) Mary E. Irwin et al. CANCER BIOLOGY & THERAPY
- Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth
- (2011) N. S. Nagaraj et al. CLINICAL CANCER RESEARCH
- Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab
- (2010) Deric L. Wheeler et al. CANCER BIOLOGY & THERAPY
- Insulin Induces Swelling-dependent Activation of the Epidermal Growth Factor Receptor in Rat Liver
- (2010) Roland Reinehr et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
- (2010) E F Dunn et al. ONCOGENE
- Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells
- (2009) Jeanett Fischgräbe et al. INTERNATIONAL JOURNAL OF CANCER
- Nuclear EGFR contributes to acquired resistance to cetuximab
- (2009) C Li et al. ONCOGENE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started